Peer-reviewed veterinary case report
Immunogene therapy trials for tumors in dogs cats and horses
By Glikin, Gerardo Claudio & Finocchiaro, Liliana María Elena·Published in TheScientificWorldJournal·2014·Unidad de Transferencia Gené·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical trials of immunogene therapy for spontaneous tumors in companion animals.
Plain-English summary
A variety of pets with different types of tumors, including dogs with melanoma and lymphoma, were treated with a new type of therapy called immunogene therapy, which helps the immune system fight cancer. This treatment used special gene delivery methods to enhance the immune response against tumors. Most pets experienced few or no side effects, and many showed improvements in their condition, such as longer survival times and better quality of life. These promising results suggest that immunogene therapy could become a standard treatment option for pets with cancer.
People also search for: dog cancer treatment options · immunogene therapy for pets · lymphoma treatment in dogs · melanoma in dogs treatment · feline fibrosarcoma therapy
Abstract
Despite the important progress obtained in the treatment of some pets' malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system's appropriate modulation may provide effective therapeutic options. In this review we summarize the outcomes of published immunogene therapy veterinary clinical trials reported by many research centers. A variety of tumors such as canine melanoma, soft tissue sarcomas, osteosarcoma and lymphoma, feline fibrosarcoma, and equine melanoma were subjected to different treatment approaches. Both viral and mainly nonviral vectors were used to deliver gene products as cytokines, xenogeneic tumor associated antigens, specific ligands, and proapoptotic regulatory factors. In some cases autologous, allogenic, or xenogeneic transgenic cytokine producing cells were assayed. In general terms, minor or no adverse collateral effects appeared during this kind of therapies and treated patients usually displayed a better course of the disease (longer survival, delayed or suppressed recurrence or metastatic spread, and improvement of the quality of life). This suggests the utility of these methodologies as standard adjuvant treatments. The encouraging outcomes obtained in companion animals support their ready application in veterinary clinical oncology and serve as preclinical proof of concept and safety assay for future human gene therapy trials.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25506617/